ASPREE试验参与者基线特征
ASPREE是一项在初级保健机构开展的随机双盲安慰剂对照试验,纳入无心血管疾病、痴呆或身体残疾且无阿司匹林禁忌或适应证的老年人(非少数族裔70岁以上,美国少数族裔65岁以上),评估每日100毫克肠溶阿司匹林能否延长无残疾和无痴呆生存。共招募澳大利亚16703人和美国2411人,中位年龄74岁(范围65-98),女性占56%,美国队列约55%来自少数族裔。
要点
- ASPREE纳入无心血管疾病、痴呆或身体残疾的社区老年人,评估低剂量阿司匹林一级预防的老年结局。
- 主要复合终点为死亡、新发痴呆或持续性身体残疾。
核心结论
- ASPREE将评估每日100毫克肠溶阿司匹林能否延长健康老年人的无残疾和无痴呆生存,并判断获益是否大于风险。
研究设计与样本
- ASPREE是在初级保健机构开展的随机双盲安慰剂对照试验,纳入非少数族裔70岁以上或美国少数族裔65岁以上、无心血管疾病、痴呆或身体残疾且无阿司匹林禁忌或适应证的老年人。
- 共招募澳大利亚16703人和美国2411人,中位年龄74岁(范围65-98),女性占56%,美国队列约55%来自少数族裔。
主要发现
- 总队列中高血压、超重和慢性肾脏病的比例与两国年龄匹配人群相似,但糖尿病、血脂异常和骨关节炎的比例较低。
- 基线评估包括体格与生活方式、个人及家族病史、血红蛋白、空腹血糖、肌酐、血脂、尿白蛋白与肌酐比值、认知(3MS、HVLT-R、COWAT、SDMT)、情绪(CES-D-10)、身体功能(步速、握力)、Katz日常生活活动能力和生活质量(SF-12)。
关键数值与推荐
- 主要复合终点为死亡、新发痴呆或持续性身体残疾。
- 干预为每日100毫克肠溶阿司匹林,评估5年内的效果。
临床怎么用
- 该试验结果将适用于两国较健康的老年人群,为低剂量阿司匹林在延长独立生活方面的获益与风险权衡提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks. METHODS: Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12). RESULTS: Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis. DISCUSSION: Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.
引用
- McNeil JJ, Woods RL, Nelson MR, et al. Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study. J Gerontol A Biol Sci Med Sci. 2017. PMID: 28329340. doi:10.1093/gerona/glw342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。